Zynex, Inc. (formerly Zynex Medical) was founded in 1996 by Thomas Sandgaard in Englewood, Colorado, as a developer and manufacturer of non-invasive medical devices focused on pain management, rehabilitation, and monitoring solutions. At its peak in the early 2010s, the company rode the wave of growing demand for electrotherapy and TENS (transcutaneous electrical nerve stimulation) units, expanding into hospital monitoring and neurodiagnostics.
The company went public in 2001 and restructured in 2010 into three subsidiaries: Zynex Medical (core pain/rehab devices), Zynex Monitoring Solutions, and Zynex NeuroDiagnostic, achieving Nasdaq listing (ZYXI) and steady revenue growth in a market projected to expand at 9% annually for pain devices. By 2022, Zynex reported approximately $48 million in annual revenue, bolstered by direct-to-consumer sales and Medicare reimbursements averaging $400 per TENS unit and $32 monthly for supplies, positioning it as a niche player in chronic pain therapy amid an opioid crisis.
The downfall accelerated in 2023–2025, triggered by a cascade of reimbursement pressures, compliance failures, and leadership missteps.
| Date | Event | Impact |
|---|---|---|
| May 2023 | Accounting experts flag aggressive revenue recognition and inventory practices as "red flags," raising doubts on earnings quality. | Erodes investor confidence; stock begins volatile trading. |
| June 2024 | Class-action lawsuits emerge over alleged misleading disclosures on sales practices; stock drops 5% in a day on heavy volume. | Signals deepening legal risks; market cap halves from $200M peak. |
| July 2025 | TriCare suspends payments over billing disputes; CEO Sandgaard ousted amid layoffs and a shareholder lawsuit; new CEO Steven Dyson appointed. | Revenue lifeline severed; Q2 cash burn spikes. |
| Nov 2025 | Q3 earnings reveal 73% YoY revenue plunge to $13.4M, $42.9M net loss (including $30.7M impairment); $1.5M interest payment missed on $60M convertible notes due May 2026. | Liquidity crisis forces Chapter 11 prep; stock tumbles 19.5%. |
| Dec 15, 2025 | Voluntary Chapter 11 filing in Texas; Nasdaq delisting notice issued, trading suspended Dec 24. | Equity value evaporates; shifts to OTC Pink (ZYXIQ). |
| Jan 21, 2026 | DOJ indicts former CEO Sandgaard and execs for healthcare and securities fraud involving millions in false Medicare/TriCare claims. | Exposes systemic fraud; further erodes creditor trust. |
These pivots transformed a compliant growth story into a fraud-tainted collapse, exacerbated by macro reimbursement cuts — Medicare TENS payments were slashed from $400 to $65 per unit.
As of February 15, 2026, Zynex remains in voluntary Chapter 11 bankruptcy, filed December 15, 2025, in the U.S. Bankruptcy Court for the Southern District of Texas (Case No. 25-90810), jointly administered for Zynex and its subsidiaries. The process is in the solicitation phase: on February 7, 2026, the company filed its Third Amended Combined Disclosure Statement and Joint Plan of Reorganization, incorporating a global settlement with key creditors and beginning vote solicitation from stakeholders. The bar date for proofs of claim passed February 10, 2026, locking in creditor claims. Operations continue under $22.3M in debtor-in-possession (DIP) financing.
Recent 8-Ks (January 29 and February 7, 2026) confirm plan advancements and forward-looking statements on emergence, tempered by equity dilution risks. The sole press release from the past week (February 4, 2026) announces in-network status with Humana effective February 1 — potentially aiding post-emergence reimbursement, but not altering acute distress.
Zynex's implosion stems from a toxic blend of internal rot and external headwinds, with fraud as the accelerant. The 60/40 split between internal and external factors may even understate the primacy of internal fraud. The external reimbursement cuts were a headwind for the entire industry — they were only fatal for Zynex because the company was already hemorrhaging from self-inflicted wounds. Fraud wasn't just an accelerant; it was the underlying disease.
- Medicare/TriCare TENS reimbursement cuts ($400 → $65/unit; $32 → $10/month)
- July 2025 TriCare suspension over billing disputes (~20% of revenue halted)
- Broader payer crackdown on durable medical equipment
- Sector-wide opioid-alternative scrutiny intensifying
- Over-reliance on Medicare/TriCare (>80% of revenue) with no diversified channels
- SG&A ballooned 50% YoY by mid-2025 despite flat sales
- Management prioritized aggressive growth over compliance
- High-volume billing via uncontrolled independent contractor network
The Lethal Blows
- Fraudulent Billing Scheme: Indicted execs orchestrated millions in false claims for unneeded devices and supplies — including upcoding, medically unnecessary equipment delivered without patient confirmation, and alleged kickbacks. Revenue was inflated 20–30% artificially. When this house of cards collapsed, it didn't just sever a contract; it destroyed the company's entire sales and billing methodology.
- Liquidity Freeze: The $1.5M interest default (November 2025) on $60M convertible notes froze credit facilities, forcing the Chapter 11 filing.
- Asset Impairment Bomb: A $30.7M non-cash write-down (Q3 2025) on goodwill and inventory exposed overvalued acquisitions and obsolete stock, signaling the end of the going concern.
In sum, fraud masked reimbursement erosion until it couldn't, culminating in a 73% revenue cliff and a $43M quarterly loss.
Red flags surfaced 12–24 months pre-filing (mid-2024 to mid-2025), blending quantitative deterioration and qualitative alarms. Investors ignored them amid a bull market for medtech, but they screamed distress.
Quantitative Signals
- Declining Altman Z-Score: Dropped below 1.8 (distress zone) by Q1 2025 from 2.5 in 2023, driven by eroding working capital and leverage spike (debt/EBITDA >5×). Working capital to total assets fell approximately 40%.
- DSO vs. Accounts Receivable: Days sales outstanding climbed to 120+ days by Q2 2025 (from 80 in 2023). A/R ballooned 25% YoY while sales stagnated — a massive red flag indicating booked sales but no cash collection, likely because claims were being rejected or products were shipped to patients who didn't order them.
- Cash Burn Acceleration: Negative free cash flow widened from –$2M/quarter (2024) to –$6.3M/quarter (Q3 2025), with cash reserves halving to $13.3M.
Qualitative Signals
- Abrupt CEO Departure: Sandgaard's July 2025 ouster amid the TriCare halt and layoffs; Dyson installed for "growth," but it masked an active fraud probe.
- Vague Guidance: Q1 2025 earnings dodged reimbursement risks, projecting "mid-teens growth" that missed by 50%; repeated delays in 10-Q filings.
- Regulatory Whispers: June 2024 lawsuits cited "material weaknesses" in internal controls. Historical FDA warnings (2014) on adverse events foreshadowed compliance lapses.
| Red Flag | What It Looked Like | What It Meant |
|---|---|---|
| Unsustainable Billing Mix | >80% of revenue from Medicare/TriCare | A single payer policy change or audit could — and did — destroy the company. A healthy company has a diversified payer mix. |
| 1099 Sales Force Reliance | Heavy use of independent contractors for sales | Reduces corporate control and increases fraud risk; the company can claim plausible deniability while reaping illicit benefits. A classic DME fraud red flag. |
| DSO vs. A/R Divergence | DSO at 120+ days while A/R grew 25% with flat sales | Revenue was "fake" in a cash flow sense — products shipped to patients who didn't order them, or claims being systematically rejected by payers. |
| Inventory vs. Sales Divergence | Inventory growth outpacing sales growth | Either product obsolescence or units produced to support a fraudulent sales scheme. This foreshadowed the $30.7M write-down directly. |
The initial assessment of a 70% probability of successful Chapter 11 confirmation appears too optimistic given the fraud overhang. The DOJ indictment is not a "tail risk" — it is a gaping wound with potentially catastrophic implications for any restructuring plan.
Why the Fraud Changes Everything
- Treble Damages Exposure: Under the False Claims Act, the government can seek triple the amount defrauded. If the alleged fraud is "in the millions," this liability could easily reach $50M–$100M+, dwarfing the current restructuring plan.
- Federal Program Exclusion: A conviction could lead to exclusion from Medicare/Medicaid entirely. If 80%+ of revenue came from federal reimbursements, this renders the company valueless as a going concern. The Humana deal is a positive signal, but commercial payers cannot replace federal programs at scale.
- DOJ Super-Priority: The DOJ is not a creditor you can settle with in the same way as bondholders. A DOJ monetary judgment could take super-priority administrative status, blowing a hole in the plan's liquidity projections.
- Asset Value Impairment: The TENS/electrotherapy IP market is crowded. Any buyer would be acquiring a lawsuit target, not a premium asset. The most likely acquirer would be a competitor seeking a fire-sale price, not a going-concern premium.
Equity Outcome
The plan explicitly warns of "significant loss" for shareholders, with creditors receiving priority recovery via debt-for-equity swaps and new shares. Existing equity receives warrants at best, with dilution exceeding 99%. Probability of common equity retaining material value: <5%. Even in the most optimistic emergence scenario, the stock would likely trade in low single digits due to massive dilution and permanent reputational damage — not a return to former highs.
ZYXIQ represents a textbook "gambler's ruin" scenario: ultra-high volatility (beta >3× market, 50%+ daily swings on news), razor-thin liquidity (<100K shares/day on OTC Pink, bid-ask spreads of 20–50%), and binary event overhangs. Speculators face total loss probability exceeding 80%, with lottery-ticket upside (10× in a miracle emergence) reserved only for those with steel nerves and sub-1% portfolio allocation.
Death Spiral Triggers
-
01
DOJ Action Escalation Any news of a large fine, guilty plea, or government seeking exclusion from federal programs would trigger an immediate 80–90% gap-down on OTC markets.
-
02
Plan Rejection If creditors or the DOJ vote down the reorganization plan, the stock could collapse in a single trading session on OTC markets with no circuit breakers.
-
03
DIP Lender Pullback If lenders perceive DOJ risk as unquantifiable, they can cut off the $22.3M facility, forcing an immediate conversion to Chapter 7 liquidation.
-
04
Additional Fraud Clawbacks DOJ False Claims Act recoveries could exceed $50M in treble damages, overwhelming the restructuring plan's liquidity assumptions entirely.
The "Lottery Ticket" Scenario — Refined
For equity to retain any value, all of the following must occur simultaneously:
- The DOJ settles for a manageable fine under $10M
- The company emerges from bankruptcy with sufficient debt wiped clean
- The business model — now reliant on commercial payers like Humana — proves it can generate positive cash flow
- No further regulatory or Medicare exclusion orders are issued
This scenario carries a probability of approximately 5%. Even if achieved, shares would trade in low single digits due to massive dilution and permanent reputational damage — not a recovery to prior highs. This is not a high-risk investment. It is a security whose value is mathematically and legally destined toward zero.
Zynex's collapse was not a "failure" in the traditional sense — it was the implosion of a business model predicated on fraud. The Chapter 11 process is not a genuine turnaround attempt but rather a structured liquidation of assets under court supervision. The primary goal is to maximize value for secured lenders and settle with the government, not to preserve equity.
The fraud was not an accelerant applied to an otherwise viable business. It was the underlying disease. External reimbursement pressures made the fraud impossible to sustain and a legitimate pivot unattainable in the available time window. When the TriCare suspension and DOJ probe converged, the company had no legitimate revenue model to fall back on.
For a speculator, ZYXIQ is not a high-risk investment — it is a security whose value is mathematically and legally destined for zero, with a minuscule probability of a technical bounce that would still leave investors with catastrophic losses relative to any reasonable cost basis. The warrants offered to equity holders in the plan will likely carry strike prices so far above any post-emergence market value as to be functionally worthless.
Zynex Medical represents a cautionary case study in how regulatory dependence, fraudulent revenue inflation, and single-channel payer concentration can converge into a total collapse. The early warning signs — DSO divergence, A/R growth without cash conversion, independent contractor over-reliance, reimbursement concentration — were textbook harbingers that went unheeded. The lesson is not that the company failed to pivot; it is that there was never a legitimate business beneath the fraud to pivot from.